+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 90Years
All Genders
ID07363811

Studying Large Granular Lymphocytes as a Predictor of Treatment Response in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab

Led by Necmettin Erbakan University · Updated on 2026-01-26

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the relationship between large granular lymphocytes LGLs and treatment outcomes in participants with metastatic non-small cell lung cancer NSCLC receiving nivolumab as a second-line therapy. LGLs are a type of large lymphocyte, mostly natural killer cells or T lymphocytes, which cannot be measured by standard blood tests but can be detected by peripheral smear. This study aims to understand how baseline and three-month LGL levels relate to treatment response and clinical parameters in these patients. Participants with metastatic NSCLC will be observed while receiving nivolumab, an immune checkpoint inhibitor targeting PD-1, which has shown meaningful survival benefits compared to chemotherapy. The study focuses on measuring LGL levels at the start and after three months of treatment. Nivolumab is approved for second-line use in advanced NSCLC following platinum-based chemotherapy. This observational study does not involve assigning treatments but follows patients receiving standard care with nivolumab. During the study, participants will undergo evaluations including objective response rate assessments according to RECIST 1.1 criteria up to 12 weeks, with longer-term monitoring of progression-free survival and overall survival from July 2025 through July 2027. Researchers will collect clinical data and monitor safety outcomes while tracking LGL levels to assess their prognostic value. The study is expected to provide insights over approximately two years of follow-up.

CONDITIONS

Brief Title

Large Granular Lymphocytes in mNSCLC Treated With Nivolumab

Research Team

A

Ahmet Oruç MD

M

Mehmet Artaç MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here